Materialise Nv (MTLS) Stock Analysis and Metrics

Materialise

NASDAQ: MTLS

$6.54 ▲ +0.11 (+1.68%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap378.50 Mn

P/E32,239.04

P/S1.22

Div. Yield0.00

ROIC (Qtr)0.00

Total Debt (Qtr)53,700.06

Revenue Growth (1y) (Qtr)-0.16

Add ratio to table…

About

Materialise NV is a leading provider of additive manufacturing and medical software tools and sophisticated 3D printing services. The company empowers customers’ use of additive manufacturing technology in general and enables specific and significant applications of additive manufacturing in particular, seeking to empower the choice for sustainability through the use of additive manufacturing.

Materialise NV generates revenue through the sale of software licenses, maintenance contracts, hardware controller sales, custom software development services, medical software and personalized medical devices, and 3D printing services for industrial customers. The company also offers consultancy, training, engineering services, and scanning solutions for its eyewear and footwear business. Its customers span a wide variety of industries including healthcare, automotive, aerospace, art and design, and consumer products.

The company operates through the following segments: Materialise Software, Materialise Medical, and Materialise Manufacturing.

• Materialise Software offers proprietary software worldwide through programs and platforms that enable companies to set up efficient, reliable and sustainable 3D printing production. The segment generates revenue from software licenses, maintenance contracts, hardware controller sales for Materialise Controllers, custom software development services, consultancy, and training services. Key software products include Magics, CO-AM, Streamics, 3-matic, Build Processors, e-Stage, Identify3D, and Layer Analysis.

• Materialise Medical provides medical software and personalized medical devices. Revenue is generated through the sale of medical software licenses, maintenance contracts, custom software development, engineering services, and 3D printed medical devices such as surgical guides and patient-specific implants. The segment serves academic institutions, medical device companies, hospitals, and research institutes.

• Materialise Manufacturing primarily offers 3D printing services to industrial customers, with a focus on Europe. Revenue comes from the sale of printed parts, scanners (such as foot scan plates for Materialise Motion), software solutions in the eyewear and footwear business, and consulting services. The segment provides additive manufacturing solutions, specialty industrial solutions like RapidFit+, and wearables initiatives for eyewear and footwear.

Materialise NV holds a strong position in the additive manufacturing industry due to its integrated business model combining software development, 3D printing, and engineering expertise. The company faces competition from 3D printing OEMs offering closed ecosystem software, traditional CAD solution providers, and other additive manufacturing management and machine control software providers in its Software segment. In the Medical segment, it competes with companies providing image-based software, 3D printed surgical models or medical devices such as 3DSystems, Stratasys, Simpleware, and Pie Medical, as well as medical device companies commercializing 3D printed medical devices. In the Manufacturing segment, it competes with industrial 3D printing service providers including Sculpteo, Prototal, Protolabs, and Quickparts.

Materialise NV serves a diverse customer base including 3D printing machine manufacturers, production companies, contract manufacturers in automotive, aerospace, consumer goods, and hearing aid industries, external 3D printing service bureaus, medical device companies, hospitals, universities, research institutes, and industrial customers across automotive, aerospace, medtech, semiconductor, industrial goods, art and design, and consumer products industries. Specific collaboration partners in the medical segment include DePuy Synthes, Smith & Nephew, Stryker, Zimmer Biomet, Enovis, Abbott, Medtronic, and Corin.

Investment Thesis

▲ Bull case

Materialise is strategically divesting non-core businesses like RapidFit and Eyewear to sharpen its focus on high-margin, structurally growing segments such as Medical and Software, where it holds a durable competitive advantage through its integrated digital ecosystem. The recent launch of PEEK implants in the CMS market expands Materialise’s offering without requiring surgeons to adopt new processes, leveraging its Mimics technology to deepen clinical integration and lock in hospital workflows. This seamless integration capability is a key differentiator that competitors struggle to replicate, positioning Materialise to capture share in a market where customization and imaging compatibility are becoming table stakes. The divestitures free up management bandwidth and capital to accelerate R&D and go-to-market efforts in Medical, which already delivered 7% revenue growth in Q1 FY26 despite FX headwinds and has the potential for sustained low double-digit growth as structural adoption of patient-specific solutions accelerates across orthopedics and cranio-maxillofacial surgery.
The CO-AM Professional platform, now in early onboarding with 7 Magic customers and targeting full global availability by mid-June FY26, represents a material but underappreciated catalyst for recurring revenue expansion in the Software segment. By enabling workflow automation without advanced programming skills, CO-AM Professional lowers the barrier to scale additive manufacturing operations from prototyping to repeatable production—a critical shift as industries like aerospace, defense, and semicon move toward industrializing AM. This aligns with Materialise’s HP partnership on the MJF 1200 printer, where Magics Print for HP is bundled with every unit priced below $60,000, opening access to the lower-to-mid range manufacturing market. With software maintenance and license deferred revenue already at EUR 49 million and total deferred revenue at EUR 61 million, the transition to cloud subscriptions is building a predictable revenue base that could drive margin expansion as operating leverage improves, especially given the 88% YoY adjusted EBITDA growth in Software during Q1 FY26 despite flat reported revenue.
Materialise’s balance sheet remains a fortress of strength, with a net cash position of EUR 72.8 million at the end of Q1 FY26—up nearly EUR 2 million quarter-over-quarter—and gross debt reduced to EUR 60.1 million, providing significant financial flexibility to weather macroeconomic uncertainty or pursue bolt-on acquisitions in adjacent high-growth niches. The company generated EUR 5.7 million in free cash flow during Q1 FY26, reflecting disciplined capex at just EUR 1.5 million and strong operating cash flow of nearly EUR 7 million, underscoring the quality of its earnings. This financial resilience allows Materialise to continue investing in R&D (exceeding EUR 11 million in Q1 FY26, majority allocated to Medical) without compromising profitability, supporting long-term innovation in areas like PEEK implants and CT-based OrthoView 3D Hip planning—both of which enhance clinical outcomes and deepen customer stickiness within its ecosystem.

Materialise is strategically divesting non-core businesses like RapidFit and Eyewear to sharpen its focus on high-margin, structurally growing segments such as Medical and Software, where it holds a durable competitive advantage through its integrated digital ecosystem. The recent launch of PEEK implants in the CMS market expands Materialise’s offering without requiring surgeons to adopt new processes, leveraging its Mimics technology to deepen clinical integration and lock in hospital workflows. This seamless integration capability is a key differentiator that competitors struggle to replicate, positioning Materialise to capture share in a market where customization and imaging compatibility are becoming table stakes. The divestitures free up management bandwidth and capital to accelerate R&D and go-to-market efforts in Medical, which already delivered 7% revenue growth in Q1 FY26 despite FX headwinds and has the potential for sustained low double-digit growth as structural adoption of patient-specific solutions accelerates across orthopedics and cranio-maxillofacial surgery.
The CO-AM Professional platform, now in early onboarding with 7 Magic customers and targeting full global availability by mid-June FY26, represents a material but underappreciated catalyst for recurring revenue expansion in the Software segment. By enabling workflow automation without advanced programming skills, CO-AM Professional lowers the barrier to scale additive manufacturing operations from prototyping to repeatable production—a critical shift as industries like aerospace, defense, and semicon move toward industrializing AM. This aligns with Materialise’s HP partnership on the MJF 1200 printer, where Magics Print for HP is bundled with every unit priced below $60,000, opening access to the lower-to-mid range manufacturing market. With software maintenance and license deferred revenue already at EUR 49 million and total deferred revenue at EUR 61 million, the transition to cloud subscriptions is building a predictable revenue base that could drive margin expansion as operating leverage improves, especially given the 88% YoY adjusted EBITDA growth in Software during Q1 FY26 despite flat reported revenue.
Materialise’s balance sheet remains a fortress of strength, with a net cash position of EUR 72.8 million at the end of Q1 FY26—up nearly EUR 2 million quarter-over-quarter—and gross debt reduced to EUR 60.1 million, providing significant financial flexibility to weather macroeconomic uncertainty or pursue bolt-on acquisitions in adjacent high-growth niches. The company generated EUR 5.7 million in free cash flow during Q1 FY26, reflecting disciplined capex at just EUR 1.5 million and strong operating cash flow of nearly EUR 7 million, underscoring the quality of its earnings. This financial resilience allows Materialise to continue investing in R&D (exceeding EUR 11 million in Q1 FY26, majority allocated to Medical) without compromising profitability, supporting long-term innovation in areas like PEEK implants and CT-based OrthoView 3D Hip planning—both of which enhance clinical outcomes and deepen customer stickiness within its ecosystem.

▼ Bear case

Materialise’s Medical segment margin expansion may be misleading, as the 200 bps YoY decline in adjusted EBIT margin referenced in the Q&A—though not fully explained—suggests underlying pressure despite topline growth. Management attributed the Q1 FY26 Medical margin of 28% to seasonality and FX, but failed to address whether rising costs from R&D investments, increased sales and marketing spend (up 4% and 2% YoY respectively), or pricing pressures in a competitive landscape are eroding profitability. The claim that margins are “hovering just under 30%” as sustainable raises concerns that the segment may not be able to meaningfully expand beyond current levels, especially if academic market funding cuts in the U.S.—explicitly called out as a growing headwind—spread to other healthcare segments or persist longer than anticipated, undermining the low double-digit growth thesis. Without clear disclosure of gross versus net margin trends or segment-level cost allocation, investors cannot assess whether Medical’s profitability is structurally improving or merely flattered by deferred revenue recognition and favorable product mix.
The Manufacturing segment, despite sequential revenue growth in aerospace, defense, and semicon, remains a drag on overall performance, with an 8% YoY revenue decline in Q1 FY26 to EUR 23.5 million and only marginally positive adjusted EBITDA of EUR 0.3 million. Management’s assertion that Manufacturing EBITDA will turn positive for the full year 2026 lacks specificity on timing, magnitude, or the drivers behind this turnaround, particularly given continued weakness in prototyping demand—a historically significant revenue stream. The divestment of RapidFit and Eyewear, while strategically sound, removes two businesses that, though part of Manufacturing, may have provided diversification and cash flow stability during the transition. Without clear evidence that strategic focus areas like aerospace and defense can offset prototyping weakness at scale, the Manufacturing segment risks remaining a persistent liability that consumes management attention and capital without delivering meaningful contribution to group profitability.
Materialise’s guidance reaffirmation for FY26 revenue (EUR 273–283 million) and adjusted EBIT (EUR 10–12 million) appears aggressive given the macroeconomic and geopolitical uncertainty explicitly cited as persistent throughout 2026, combined with FX headwinds that materially impacted Medical and Software segments in Q1 FY26. The assumption that divestitures will be absorbed without guidance revision implies either strong offsetting growth in core segments or aggressive cost cuts—but with R&D and SG&A already rising (4% and 2% YoY), further efficiency gains may be difficult to sustain without harming long-term innovation. Moreover, the reliance on Manufacturing turning EBITDA-positive to support the EBIT range introduces execution risk, as there is no clear timeline or benchmark for when this will occur, and the segment’s sequential improvement could stall if global manufacturing PMI remains subdued or if defense spending shifts slower than expected. The lack of discussion around working capital pressures—despite a EUR 2.7 million increase in net working capital components driven by higher inventory—suggests potential hidden strain on liquidity that could constrain future investment or dividends.

Materialise’s Medical segment margin expansion may be misleading, as the 200 bps YoY decline in adjusted EBIT margin referenced in the Q&A—though not fully explained—suggests underlying pressure despite topline growth. Management attributed the Q1 FY26 Medical margin of 28% to seasonality and FX, but failed to address whether rising costs from R&D investments, increased sales and marketing spend (up 4% and 2% YoY respectively), or pricing pressures in a competitive landscape are eroding profitability. The claim that margins are “hovering just under 30%” as sustainable raises concerns that the segment may not be able to meaningfully expand beyond current levels, especially if academic market funding cuts in the U.S.—explicitly called out as a growing headwind—spread to other healthcare segments or persist longer than anticipated, undermining the low double-digit growth thesis. Without clear disclosure of gross versus net margin trends or segment-level cost allocation, investors cannot assess whether Medical’s profitability is structurally improving or merely flattered by deferred revenue recognition and favorable product mix.
The Manufacturing segment, despite sequential revenue growth in aerospace, defense, and semicon, remains a drag on overall performance, with an 8% YoY revenue decline in Q1 FY26 to EUR 23.5 million and only marginally positive adjusted EBITDA of EUR 0.3 million. Management’s assertion that Manufacturing EBITDA will turn positive for the full year 2026 lacks specificity on timing, magnitude, or the drivers behind this turnaround, particularly given continued weakness in prototyping demand—a historically significant revenue stream. The divestment of RapidFit and Eyewear, while strategically sound, removes two businesses that, though part of Manufacturing, may have provided diversification and cash flow stability during the transition. Without clear evidence that strategic focus areas like aerospace and defense can offset prototyping weakness at scale, the Manufacturing segment risks remaining a persistent liability that consumes management attention and capital without delivering meaningful contribution to group profitability.
Materialise’s guidance reaffirmation for FY26 revenue (EUR 273–283 million) and adjusted EBIT (EUR 10–12 million) appears aggressive given the macroeconomic and geopolitical uncertainty explicitly cited as persistent throughout 2026, combined with FX headwinds that materially impacted Medical and Software segments in Q1 FY26. The assumption that divestitures will be absorbed without guidance revision implies either strong offsetting growth in core segments or aggressive cost cuts—but with R&D and SG&A already rising (4% and 2% YoY), further efficiency gains may be difficult to sustain without harming long-term innovation. Moreover, the reliance on Manufacturing turning EBITDA-positive to support the EBIT range introduces execution risk, as there is no clear timeline or benchmark for when this will occur, and the segment’s sequential improvement could stall if global manufacturing PMI remains subdued or if defense spending shifts slower than expected. The lack of discussion around working capital pressures—despite a EUR 2.7 million increase in net working capital components driven by higher inventory—suggests potential hidden strain on liquidity that could constrain future investment or dividends.

Peer Comparison

Companies in the Software - Application

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	SAP	Sap Se	208.91 Bn	20.22	4.86	7.05 Bn
2	YMM	Full Truck Alliance Co. Ltd.	188.77 Bn	322.09	-	0.00 Bn
3	SHOP	Shopify Inc.	145.98 Bn	109.59	11.80	-
4	UBER	Uber Technologies, Inc	141.48 Bn	16.32	2.64	10.51 Bn
5	CRM	Salesforce, Inc.	128.51 Bn	16.95	3.00	39.28 Bn
6	NOW	ServiceNow, Inc.	98.38 Bn	54.17	7.05	7.52 Bn
7	ADP	Automatic Data Processing Inc	97.56 Bn	22.45	4.52	3.98 Bn
8	SNOW	Snowflake Inc.	91.55 Bn	-76.63	18.19	-

Research Tools

Developers

About

Investment Thesis

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Peer Comparison

Create an account

Sign In

Reset Password